Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Receives Average Rating of “Hold” from Analysts

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) has received an average recommendation of “Hold” from the five research firms that are currently covering the stock, MarketBeat.com reports. Four analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $3.33.

Separately, Wall Street Zen started coverage on Syros Pharmaceuticals in a research report on Friday, May 16th. They issued a “sell” rating for the company.

Institutional Trading of Syros Pharmaceuticals

A hedge fund recently bought a new stake in Syros Pharmaceuticals stock. Two Sigma Securities LLC purchased a new position in Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 107,742 shares of the company’s stock, valued at approximately $25,000. Two Sigma Securities LLC owned about 0.40% of Syros Pharmaceuticals as of its most recent SEC filing. 91.47% of the stock is owned by institutional investors and hedge funds.

Syros Pharmaceuticals Stock Down 12.7%

SYRS stock opened at $0.03 on Friday. Syros Pharmaceuticals has a twelve month low of $0.02 and a twelve month high of $6.93. The company has a market cap of $721,780.80, a P/E ratio of -0.01 and a beta of 1.31. The business has a fifty day moving average of $0.03 and a 200-day moving average of $0.14.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.